Overview

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Treatments:
Nivolumab